-
Detection of cis-element clusters in higher eukaryotic DNA.
Bioinformatics. 2001 Oct;17(10):878-89
PMID: 11673232
-
Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.
Br J Haematol. 1999 Oct;107(1):207-9
PMID: 10520043
-
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.
Per Med. 2007 May 1;4(2):157-169
PMID: 19802360
-
Estimation of the warfarin dose with clinical and pharmacogenetic data.
N Engl J Med. 2009 Feb 19;360(8):753-64
PMID: 19228618
-
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.
Clin Pharmacol Ther. 1974 Apr;15(4):424-30
PMID: 4821443
-
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Am J Hum Genet. 2007 Sep;81(3):559-75
PMID: 17701901
-
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Chem Res Toxicol. 1992 Jan-Feb;5(1):54-9
PMID: 1581537
-
CYP4F2 genetic variant alters required warfarin dose.
Blood. 2008 Apr 15;111(8):4106-12
PMID: 18250228
-
The pharmacodynamics of the oral anticoagulant drugs.
Prog Hemost Thromb. 1974;2(0):175-213
PMID: 4137288
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
Pharmacogenomics J. 2009 Feb;9(1):49-60
PMID: 18825162
-
Prioritizing GWAS results: A review of statistical methods and recommendations for their application.
Am J Hum Genet. 2010 Jan;86(1):6-22
PMID: 20074509
-
Factors influencing warfarin dose requirements in African-Americans.
Pharmacogenomics. 2007 Nov;8(11):1535-44
PMID: 18034618
-
The association of vitamin K status with warfarin sensitivity at the onset of treatment.
Br J Haematol. 2001 Mar;112(3):572-7
PMID: 11260056
-
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
Blood. 2008 Aug 15;112(4):1013-21
PMID: 18523153
-
Primer3 on the WWW for general users and for biologist programmers.
Methods Mol Biol. 2000;132:365-86
PMID: 10547847
-
Systematic overview of warfarin and its drug and food interactions.
Arch Intern Med. 2005 May 23;165(10):1095-106
PMID: 15911722
-
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.
JAMA. 2001 Nov 14;286(18):2270-9
PMID: 11710893
-
Human P450 metabolism of warfarin.
Pharmacol Ther. 1997;73(1):67-74
PMID: 9014207
-
TRANSFAC: an integrated system for gene expression regulation.
Nucleic Acids Res. 2000 Jan 1;28(1):316-9
PMID: 10592259
-
The structure of haplotype blocks in the human genome.
Science. 2002 Jun 21;296(5576):2225-9
PMID: 12029063
-
A new statistical method for haplotype reconstruction from population data.
Am J Hum Genet. 2001 Apr;68(4):978-89
PMID: 11254454
-
Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene.
Genomics. 2005 Sep;86(3):316-28
PMID: 15990270
-
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
Am J Hum Genet. 2004 Jan;74(1):106-20
PMID: 14681826
-
Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.
Thromb Haemost. 1999 Mar;81(3):396-9
PMID: 10102468
-
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics. 2008 Oct;9(10):1445-58
PMID: 18855533
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Clin Pharmacol Ther. 2004 Mar;75(3):204-12
PMID: 15001972
-
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
Chest. 1998 Nov;114(5 Suppl):445S-469S
PMID: 9822057
-
Management and dosing of warfarin therapy.
Am J Med. 2000 Oct 15;109(6):481-8
PMID: 11042238
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
N Engl J Med. 2005 Jun 2;352(22):2285-93
PMID: 15930419
-
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Blood. 2010 May 6;115(18):3827-34
PMID: 20203262
-
Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols.
Am J Med. 2004 May 15;116(10):651-6
PMID: 15121490
-
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Pharmacogenomics. 2008 May;9(5):511-26
PMID: 18466099
-
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
Pharmacogenet Genomics. 2010 Jul;20(7):407-13
PMID: 20442691
-
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
J Thromb Haemost. 2010 Jan;8(1):95-100
PMID: 19874474
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Clin Pharmacol Ther. 2008 Sep;84(3):326-31
PMID: 18305455
-
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.
Clin Pharmacol Ther. 2008 Sep;84(3):332-9
PMID: 18596683
-
Genetic and clinical predictors of warfarin dose requirements in African Americans.
Clin Pharmacol Ther. 2010 Apr;87(4):459-64
PMID: 20072124
-
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
PLoS Genet. 2009 Mar;5(3):e1000433
PMID: 19300499
-
Sequence diversity and haplotype structure at the human CYP3A cluster.
Pharmacogenomics J. 2006 Mar-Apr;6(2):105-14
PMID: 16314882
-
Patient-specific factors predictive of warfarin dosage requirements.
Ann Pharmacother. 2002 Oct;36(10):1512-7
PMID: 12243598